Remix Therapeutics develops small molecule therapies that modulate RNA processing to target disease-driving mRNAs and proteins. Their proprietary REMaster™ platform enables the identification of druggable targets in diseases with high unmet medical need, advancing new therapeutic options for patients.
Funding
$213M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
TCFounders
Product
Problem
Many diseases are driven by errors in RNA processing, leading to the production of aberrant proteins. Traditional drug discovery methods often struggle to target these complex RNA-related mechanisms effectively. This creates a significant unmet need for therapies that can precisely modulate RNA processing to treat the underlying causes of disease.
Solution
Remix Therapeutics is developing small molecule therapies designed to modulate RNA processing, thereby addressing the root causes of disease. Their REMaster™ platform enables the identification of druggable targets within RNA processing pathways. By harnessing cellular machinery, Remix's approach aims to control RNA processing and modulate the expression of disease-driving mRNAs and proteins. This allows for the development of new therapeutic options for diseases with high unmet medical needs. The company's approach involves identifying high-value targets, functional target validation, and compound optimization from a proprietary library.
Target Audience
The primary target audience includes patients suffering from diseases driven by errors in RNA processing, as well as healthcare providers seeking novel therapeutic options for these conditions.
Features
- REMaster™ platform for identifying druggable targets in RNA processing.
- Small molecule therapies designed to modulate RNA processing.
- Focus on diseases with high unmet medical needs.
- In-house technology platform for rapid drug discovery program generation.
- Clinical-stage programs advancing towards the clinic.
- Expertise in data science, biology, biomolecular sciences, medicinal and computational chemistry.